Search results
Showing 151 to 164 of 164 results for metastatic breast cancer
NICE draft guidance does not recommend tucatinib for advanced breast cancer
NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.
NICE has today (20 April 2021) published draft guidance recommending trastuzumab deruxtecan for use in the Cancer Drugs Fund (CDF) for treating a type of breast cancer called HER2 positive breast cancer which can’t be surgically removed or which has spread to other parts of the body.
NICE draft guidance recommends abemaciclib for advanced breast cancer
NICE has today published draft guidance which recommends twice-daily pill abemaciclib (also called Verzenios and made by Eli Lilly) as an option for adults with a type of breast cancer called hormone receptor-positive, HER2-negative breast cancer which has spread to other parts of the body.
Uptake of NICE-approved medicines on the NHS to treat cardiovascular disease, diabetes and osteoporosis is higher than expected, latest figures reveal.
NICE approves routine use of drug combination for advanced breast cancer
Another life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS following its approval by NICE in final draft guidance published today (23 September 2022).
Draft guidance published today (8 March 2022) by NICE for public consultation does not recommend pembrolizumab plus chemotherapy for treating triple negative breast cancer that has spread to other parts of the body.
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
NICE recommends Piqray and Trodelvy, maintaining 100% approvals of breast cancer drugs since 2018
An agreement with the companies on the price of 2 breast cancer treatments, Piqray and Trodelvy, has paved the way for NICE to be able to make them available immediately to around 3,450 people on the NHS and maintaining NICE’s 100% approval rate of breast cancer drugs since 2018.
NICE says new triple negative advanced breast cancer drug too expensive for NHS use
NICE has today, 7 April 2022, issued draft guidance which does not recommend sacituzumab govitecan for treating locally advanced or metastatic triple negative breast cancer.
NICE recommends Enhertu for more people with advanced breast cancer
Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage disease, in final draft guidance.
NICE final draft guidance adds further treatment option for triple-negative breast cancer
NICE has today (8 November 2022) published final draft guidance which recommends pembrolizumab as an option for people with a type of breast cancer called triple-negative breast cancer.
Ground-breaking commercial deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit in final draft guidance published today (6 April 2023) by NICE that recommends it for some types of early breast cancer and advanced prostate cancer.
NICE draft guidance recommends tucatinib for advanced breast cancer
Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
Thousands of breast cancer patients to have routine access to NICE-approved drug combination
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available for routine use after draft guidance from NICE today (26 February) recommended ribociclib (also called Kisqali and made by Novartis) is taken out of the Cancer Drugs Fund (CDF).